Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totalling 281,100 shares, a growth of 13.1% from the July 15th total of 248,500 shares. Based on an average trading volume of 426,000 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Investors Weigh In On Aligos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ALGS. Armistice Capital LLC lifted its position in Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares during the period. Acadian Asset Management LLC lifted its holdings in Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after buying an additional 171,490 shares during the period. Opaleye Management Inc. boosted its stake in Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after acquiring an additional 333,000 shares during the last quarter. Finally, Altitude Crest Partners Inc. acquired a new stake in Aligos Therapeutics during the 4th quarter worth $1,889,000. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Stock Performance

Shares of NASDAQ:ALGS traded up $0.04 on Friday, hitting $0.53. The stock had a trading volume of 506,986 shares, compared to its average volume of 379,329. The company has a market capitalization of $41.02 million, a price-to-earnings ratio of -0.41 and a beta of 2.18. The firm’s 50 day moving average price is $0.48 and its 200-day moving average price is $0.69. Aligos Therapeutics has a twelve month low of $0.35 and a twelve month high of $1.20.

Aligos Therapeutics shares are going to reverse split on the morning of Monday, August 19th. The 1-25 reverse split was announced on Thursday, August 15th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, August 16th.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Tuesday, August 6th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.19. The company had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative net margin of 783.72% and a negative return on equity of 144.16%. During the same period in the prior year, the firm posted ($0.43) earnings per share. As a group, sell-side analysts predict that Aligos Therapeutics will post -0.73 EPS for the current year.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).